Digital Inhaler approved for Asthma patients: FDA

AirDuo Digihaler (fluticasone propionate 113mcg and salmeterol 14mcg), an inhalation powder, has been approved by the FDA. It is meant for asthma treatment in patients aged 12 years and older, but does not give relief from sudden breathing problems and won’t replace a rescue inhaler.

It is a combination therapy digital inhaler that comes with a built-in sensor. A companion mobile application is connected to it that provide information on inhaler use to asthma patients.

Just like the ProAir Digihaler, AirDuo Digihaler make the use of the build-in sensor to detect the utilization of inhaler and measure inspiratory flow rates. With the use of Bluetooth Wireless Technology, the data is sent to a companion mobile app. This enables the patients to review their data and they have the choice to share it with their healthcare providers. They can also set reminders about their AirDuo Digihaler prescription.

The approval is based on the supplemental new drug application’s review submitted by Teva to the FDA. The Digihaler combines multi-dose dry powder inhaler with fluticasone propionate and salmeterol. It is approved in a low 55/14mcg, medium 113/14mcg and high dose 232/14mcg.